Brokers Offer Predictions for CRDF Q2 Earnings

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities research analysts at Zacks Research issued their Q2 2026 earnings estimates for Cardiff Oncology in a research report issued to clients and investors on Tuesday, May 26th. Zacks Research analyst J. Vandermosten expects that the company will earn ($0.18) per share for the quarter. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.65) per share. Zacks Research also issued estimates for Cardiff Oncology’s Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.20) EPS.

Cardiff Oncology (NASDAQ:CRDF) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Cardiff Oncology had a negative return on equity of 95.51% and a negative net margin of 8,527.43%.The business had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut Cardiff Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. Piper Sandler dropped their price objective on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cardiff Oncology in a research report on Wednesday, January 28th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $10.10.

Cardiff Oncology Stock Up 9.0%

CRDF opened at $1.94 on Wednesday. The stock’s 50 day moving average price is $1.70 and its two-hundred day moving average price is $2.06. The firm has a market capitalization of $132.64 million, a P/E ratio of -2.90 and a beta of 1.36. Cardiff Oncology has a 12-month low of $1.48 and a 12-month high of $4.56.

Hedge Funds Weigh In On Cardiff Oncology

Hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. acquired a new stake in shares of Cardiff Oncology during the 4th quarter valued at about $3,388,000. Laurion Capital Management LP lifted its stake in Cardiff Oncology by 37.2% during the third quarter. Laurion Capital Management LP now owns 2,465,872 shares of the company’s stock worth $5,080,000 after purchasing an additional 668,590 shares during the period. Acorn Capital Advisors LLC boosted its holdings in Cardiff Oncology by 39.3% during the third quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock valued at $4,042,000 after purchasing an additional 553,317 shares in the last quarter. Millennium Management LLC boosted its holdings in Cardiff Oncology by 441.5% during the fourth quarter. Millennium Management LLC now owns 194,420 shares of the company’s stock valued at $546,000 after purchasing an additional 158,519 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Cardiff Oncology by 7.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after purchasing an additional 104,409 shares during the period. Institutional investors and hedge funds own 16.29% of the company’s stock.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.